Curis, Inc. ( NASDAQ: CRIS) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...

Curis, Inc. ( NASDAQ: CRIS) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Good afternoon. I'm Jim Dentzer, the CEO of Curis. Thank you for taking time today ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. Th ...

MRI decoding reveals that the inferior frontal junction-visual network reinstates target-related information as a proxy for target localization before visual search.

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 ...